Direct answer: Survodutide and retatrutide are both next-generation GLP-1 drugs but they activate different receptor combinations. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Survodutide is a dual agonist (GLP-1 + glucagon) — it skips the GIP receptor. Both produce strong weight loss, but the head-to-head numbers favor retatrutide: ~26.6% body weight loss in Phase 3 (TRIUMPH-4) for retatrutide vs ~19% for survodutide in its Phase 2 trial. Survodutide is developed by Boehringer Ingelheim/Zealand Pharma; retatrutide by Eli Lilly.
Key Takeaways
- Retatrutide: Triple agonist — GLP-1 + GIP + glucagon receptors. Eli Lilly. Phase 3 weight loss: 26.6%.
- Survodutide: Dual agonist — GLP-1 + glucagon (skips GIP). Boehringer Ingelheim / Zealand Pharma. Phase 2 weight loss: 19% at 48 weeks.
- The GIP receptor question: GIP appears to enhance weight loss and reduce nausea when paired with GLP-1. Skipping it (as survodutide does) means survodutide loses some efficacy that retatrutide retains.
- Both add glucagon agonism, which is what separates them from tirzepatide (dual agonist, but the missing receptor is glucagon not GIP).
- Approval status: Both are investigational. Survodutide is in Phase 3 trials; retatrutide is also in Phase 3. Neither is FDA-approved.
- Survodutide is showing strong liver-fat data — Phase 2 MASH trial showed 83% of patients hit MASH resolution endpoint, comparable to or better than retatrutide's liver fat results.
- Practical implication: For pure weight loss, retatrutide currently leads. For liver fat / MASH-specific applications, survodutide may have an edge.
The Receptor Logic: Why Three vs Two Matters
Both drugs are part of the post-tirzepatide generation of obesity peptides. The receptor combinations:
| Drug | GLP-1 | GIP | Glucagon | Class |
|---|---|---|---|---|
| Semaglutide | ✅ | ❌ | ❌ | Mono-agonist |
| Tirzepatide | ✅ | ✅ | ❌ | Dual agonist |
| Survodutide | ✅ | ❌ | ✅ | Dual agonist (different pair) |
| Retatrutide | ✅ | ✅ | ✅ | Triple agonist |
| Cagrilintide | ❌ | ❌ | ❌ (amylin agonist) | Outside this framework |
The interesting thing about survodutide: it's a dual agonist like tirzepatide, but it picks glucagon instead of GIP as the second receptor.
The pharmacological tradeoff:
- GIP receptor activation → enhanced lipid handling, reduced nausea at equivalent appetite suppression
- Glucagon receptor activation → increased resting energy expenditure, hepatic fat oxidation
Tirzepatide gets the "less nausea" benefit from GIP. Survodutide gets the "burn more calories" benefit from glucagon. Retatrutide gets both.
This is why retatrutide's clinical efficacy exceeds both single-pair drugs — and why understanding which receptors a drug hits tells you what kind of weight loss profile to expect.
Weight Loss: Direct Comparison
The cleanest head-to-head comparison is across Phase 2 trial data (both drugs have Phase 2 NEJM publications):
| Drug | Phase 2 trial | N | Highest dose | Weight loss at 48 weeks |
|---|---|---|---|---|
| Semaglutide | STEP-1 (Phase 3, included for reference) | 1,961 | 2.4mg | 14.9% |
| Tirzepatide | SURMOUNT-1 (Phase 3, included for reference) | 2,539 | 15mg | 22.5% |
| Survodutide | Le Roux et al. 2024 | 387 | 4.8mg | 18.7% |
| Retatrutide | Jastreboff et al. 2023 | 338 | 12mg | 24.2% |
Phase 3 data (where available):
- Retatrutide TRIUMPH-4 (Dec 2025): 26.6% placebo-adjusted at 12mg over 68 weeks
- Survodutide Phase 3 trial: Underway in obesity and MASH populations; readout 2026–2027
Headline takeaway: At their highest tested doses, retatrutide produces about 6–8 percentage points more weight loss than survodutide. The added GIP receptor activation in retatrutide is the most likely mechanistic reason.
Liver Fat / MASH: Where Survodutide May Win
For pure weight loss, retatrutide leads. But for liver fat reduction in MASH (metabolic dysfunction-associated steatohepatitis), survodutide is showing remarkable data:
- Survodutide Phase 2 MASH trial: 83% of patients on the high dose achieved MASH resolution without worsening of fibrosis — among the strongest data points ever reported for MASH therapy.
- Retatrutide Phase 2 liver substudy: Up to 80% reduction in liver fat content (MRI-PDFF) at 12mg, but MASH resolution rates haven't been published yet.
If you're choosing between these drugs primarily for liver disease (NAFLD/MASH), survodutide may have an edge based on the most recent published data. For pure weight loss, retatrutide currently leads.
Dosing and Pharmacokinetics
| Property | Survodutide | Retatrutide |
|---|---|---|
| Half-life | ~7 days | ~6 days |
| Dosing frequency | Once weekly | Once weekly |
| Starting dose | 0.3–1.2mg | 0.5–2mg |
| Maximum studied dose | 6mg (Phase 2) | 12mg |
| Titration interval | 4 weeks | 4 weeks |
| Administration | Subcutaneous | Subcutaneous |
| Form | Lyophilized vials + reconstitution | Lyophilized vials + reconstitution |
Both drugs use once-weekly subcutaneous injection with similar pharmacokinetics. Survodutide's lower top dose (6mg vs 12mg) reflects different Phase 2 study designs, not necessarily a ceiling on the drug.
Side Effect Profile Comparison
| Side Effect | Survodutide (Phase 2) | Retatrutide (Phase 3 12mg) |
|---|---|---|
| Nausea | ~46% | 43% |
| Vomiting | ~26% | 21% |
| Diarrhea | ~28% | 33% |
| Constipation | ~22% | 25% |
| Dysesthesia | Not reported | 21% |
| Discontinuation due to AE | ~20% | 14% |
Two patterns stand out:
- Nausea is comparable between the drugs — both hit similar GI thresholds.
- Dysesthesia is unique to retatrutide — survodutide doesn't produce this signal.
- Survodutide has higher dropout in Phase 2 — possibly because GIP receptor activation (present in retatrutide, absent in survodutide) reduces nausea at equivalent appetite suppression.
Approval Status and Availability
| Property | Survodutide | Retatrutide |
|---|---|---|
| FDA approval | Not approved | Not approved |
| Phase 3 status | Ongoing | Topline reported, full data 2026 |
| Earliest realistic approval | 2027–2028 | 2026–2027 |
| Compounding pharmacy availability | Very limited | Wider availability |
| Research peptide availability | Limited but growing | Established research-peptide market |
Retatrutide has a small lead in development timeline and a much larger lead in research-peptide market availability. For users wanting to access either drug today via research-use channels, retatrutide is significantly easier to source.
Mechanism Differences: Why the Numbers Differ
The receptor combination drives the weight loss difference:
Survodutide (GLP-1 + glucagon):
- Appetite suppression from GLP-1 → eat less
- Increased resting energy expenditure from glucagon → burn more at rest
- Missing: GIP's contribution to lipid handling and reduced nausea
Retatrutide (GLP-1 + GIP + glucagon):
- Appetite suppression from GLP-1 → eat less
- Improved lipid metabolism from GIP → less fat storage
- Increased resting energy expenditure from glucagon → burn more at rest
- All three pathways operating simultaneously
The 6–8% weight loss difference at the same trial duration mostly reflects the GIP receptor contribution. For the full mechanism story, see retatrutide mechanism of action.
Choosing Between Them
If you were comparing the two drugs (hypothetically — neither is approved for use):
Choose retatrutide if your primary goal is:
- Maximum body weight loss
- Already a triple-agonist signal you've seen work in others
- Access via research-use channels (easier sourcing)
Choose survodutide if your primary goal is:
- Liver fat / MASH-specific treatment
- Slightly different side effect profile (no dysesthesia signal)
- Backing from Boehringer Ingelheim (specific to non-US markets where BI's pipeline may launch first)
For most users, retatrutide is the more practical choice today. Survodutide's edge cases (MASH, dysesthesia-free profile) are real but narrow.
Frequently Asked Questions
What is survodutide? Survodutide (BI 456906) is an investigational dual agonist drug developed by Boehringer Ingelheim and Zealand Pharma that activates GLP-1 and glucagon receptors. It's in Phase 3 trials for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It's not FDA-approved.
How is survodutide different from retatrutide? Survodutide activates two receptors (GLP-1 + glucagon); retatrutide activates three (GLP-1 + GIP + glucagon). The missing GIP receptor in survodutide explains most of the efficacy gap — retatrutide produces 6–8% more weight loss than survodutide at comparable doses, likely because GIP enhances weight loss and reduces nausea.
Which is better, survodutide or retatrutide? For weight loss, retatrutide currently leads — 26.6% Phase 3 vs 18.7% survodutide Phase 2. For liver fat / MASH specifically, survodutide has shown remarkable Phase 2 results (83% MASH resolution rate). For most users primarily seeking weight loss, retatrutide is the stronger choice.
Are both drugs FDA-approved? Neither survodutide nor retatrutide is FDA-approved as of 2026. Both are in Phase 3 trials. Retatrutide is slightly ahead in development timeline (TRIUMPH-4 topline already released; survodutide Phase 3 still ongoing).
Why does the missing GIP receptor matter? GIP receptor activation, when paired with GLP-1, appears to enhance weight loss and reduce nausea at equivalent appetite suppression. Tirzepatide demonstrated this benefit. Survodutide skips GIP and goes straight to glucagon, missing the GIP-paired benefit. Retatrutide gets both.
Can I take survodutide instead of retatrutide? Neither is approved for general use. If you're considering investigational/research-use access, retatrutide is significantly easier to source in 2026. Survodutide is largely limited to clinical trial enrollment until its Phase 3 program completes and Boehringer Ingelheim submits an NDA.
Will survodutide replace retatrutide? Unlikely. The triple-agonist mechanism in retatrutide gives it a higher efficacy ceiling. Survodutide will likely find a niche in liver disease (MASH) and possibly as a tirzepatide alternative for users who don't tolerate the GIP receptor's effects. Retatrutide and tirzepatide will likely dominate the obesity market.
Where can I read more about retatrutide's mechanism vs survodutide's?
- Retatrutide mechanism of action — the full triple-agonist deep-dive
- Retatrutide vs tirzepatide — closer dual-vs-triple comparison
- Retatrutide vs semaglutide — the broader receptor-count comparison
Medical Disclaimer: Both survodutide and retatrutide are investigational compounds not FDA-approved for any indication as of 2026. This article compares published Phase 2 and Phase 3 clinical trial data for educational purposes only. Trial outcomes and approval timelines may change as new data emerges. Consult a qualified healthcare provider before considering any peptide protocol; do not self-administer investigational drugs based on article comparisons.